Background: The plasma levels of amino terminal pro-B type natriuretic peptide (NT-proBNP) have been found to be useful in evaluating children with heart failure in developed countries where the cause is mainly structural heart lesions. There is paucity of similar studies from developing countries where the causes are mostly of infectious origin. This article is aim to evaluate the relationship between plasma NT-proBNP levels and the severity, outcome and duration of admission of children with heart failure.
Methods: The subjects were children presenting to the children's emergency room (CHER) diagnosed with heart failure based on the modified Ross criteria. The controls were age matched well children recruited from follow up clinics. Information on bio-data and socio-demographics was collected while blood was obtained for plasma NT-proBNP measurement. Data analysis was done with SPSS.
Results: One hundred and twenty six subjects and same number of controls aged 2 months to 13 years were recruited. The mean plasma NT-proBNP in the subjects was 1,137.10±1,243.78 ng/L and in controls, 578.00±665.08 ng/L (t=5.669, P<0.001). Subjects with severe heart failure had a statistically significantly higher mean plasma NT-proBNP than those with mild or moderate categories (P<0.001). A plasma NT-proBNP of 903.15 ng/L had a 73.3% sensitivity and 72.1% specificity for identifying severe heart failure using receiver operating curve (ROC) analysis (95% CI, 0.659-0.912, P<0.001).
Conclusions: Children with heart failure had significantly higher mean NT-proBNP value than controls and the value was highest in those with severe form of heart failure compared to those with moderate or mild categories. Plasma NT-proBNP should be determined for children presenting with clinically diagnosed heart failure to identify those with severe heart failure and institute prompt treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582059 | PMC |
http://dx.doi.org/10.21037/cdt.2017.05.08 | DOI Listing |
ESC Heart Fail
December 2024
Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Aims: Patients with cardiomyopathies are a heterogeneous group of patients who experience high morbidity and mortality. Early cardiac assessment and intervention with access to genetic counselling in a multidisciplinary Cardiomyopathy Clinic may improve outcomes and prevent progression to advanced heart failure.
Methods And Results: Our prospective cohort study was conducted at a multidisciplinary Cardiomyopathy Clinic with 421 patients enrolled (42.
BMC Cardiovasc Disord
December 2024
Jiangxi University of Chinese Medicine, Jiangxi, China.
Background: Qi Li Qiang Xin (QLQX) capsule has a solid theoretical basis and clinical efficacy in the treatment of chronic heart failure; however, the underlying mechanisms remain obscure. This study was designed to determine the effect of the QLQX on the treatment of heart failure and delineate the underlying mechanisms via a nontargeted metabolomics and lipidomics approach.
Methods: A rat model of heart failure after myocardial infarction (MI) was established via permanent ligation of the anterior descending branch of the left coronary artery.
Int Immunopharmacol
December 2024
Department of Critical Care Medicine, the First Affiliated Hospital of Jinan University, Guangzhou 510632, Guangdong, China. Electronic address:
Previous studies demonstrated that dexmedetomidine (Dex) posttreatment aggravated myocardial dysfunction and reduced survival in septic mice. Yet, whether Dex elicits similar effects in septic patients as defined by Sepsis-3 remains unknown. This study sought to assess the effects of Dex-based sedation on mortality and cardiac dysfunction in septic patients defined by Sepsis-3 and to further reveal the mechanisms in septic rats.
View Article and Find Full Text PDFJ Med Biochem
September 2024
Xingtai Third Hospital, Cardiology Ward 2, Xingtai, China.
Background: The aim of the study was to examine the significance of plasma Transforming Growth Factor-1/TGF-β1 (TGF-β1) level testing in patients with Type 2 Diabetes Mellitus (T2DM) and heart failure.
Methods: A sample of T2DM patients who were hospitalised for dyspnea was chosen between June 2021 and June 2023. Based on the convenience sample approach, 150 cases were screened for the study, and 50 healthy non-diabetic people without cardiac problems who completed physical examinations over the same period were included as a control group.
Br J Anaesth
December 2024
Translational Medicine and Therapeutics, William Harvey Research Institute, Queen Mary University of London, London, UK. Electronic address:
Background: Hypertension therapy in older adults is often suboptimal, in part because of inadequate suppression of the renin-angiotensin-aldosterone system (RAAS). We hypothesised that distinct endotypes of RAAS activation before noncardiac surgery are associated with increased risk of myocardial injury.
Methods: This was a prespecified exploratory analysis of a multicentre randomised controlled trial (ISRCTN17251494) which randomised patients ≥60 yr old undergoing elective noncardiac surgery to either continue or stop RAAS inhibitors (determined by pharmacokinetic profiles).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!